Skip to main content
padlock icon - secure page this page is secure

Highly Pure Phospholipids Based Brain Docosahexaenoic Acid Transporters

Buy Article:

$63.00 + tax (Refund Policy)

The most common age-dependent neurodegenerative disorders such as dementia and Alzheimer's disease have become an urgent public health problem in the most areas of the world. The strategy of the current therapy focuses on increasing availability of brain acetylcholine concentration, and use of acetylcholinesterase inhibitors has become the main approach to symptomatic treatment. However, an ideal drug for the disorders should enable to both simultaneously delay or halt the underlying pathological process and improve memory. The present paper describes an alterative cholinergic strategy to memory enhancement by the exogenous introduction of highly enriched docosahexaenoic acid (DHA) - containing molecular species of highly pure phospholipids and highly pure ether phospholipids based brain DHA transporters to promote survival of aged basal forebrain cholinergic neurons (BFCNs) through reversing abnormal levels of neural membrane DHA aminophospholipids. This results in significantly improving neural membrane fluidity and gap capacity leading to further recovering the expression of the p75 neurotrophin receptor and then failed retrograde nerve growth factor signaling, followed by promoting the choline acetyltransferase activity in the BFCNs. The pre-clinical results shown in published patents and recent applications to support the proposed therapeutic mechanism of the brain DHA transporters are summarized. The advantage of the potential drugs in both the prevention and treatment of agedependent basal forebrain cholinergic dysfunction related neurodegenerative disorders is further discussed.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Alzheimer's disease; Phospholipids; age-dependent cholinergic neurodegeneration; choline acetyltransferase; dementia; docosahexaenoic acid; ether phospholipids; lipid metabolism; lysophosphatidylcholine; lysophosphatidylethanolamine; p75 neurotrophin receptor; phosphatidyl-monomethylethanoamine; phosphatidylcholine; phosphatidylethanolamine; phosphatidylserine

Document Type: Research Article

Publication date: 01 June 2010

More about this publication?
  • Recent Patents on CNS Drug Discovery publishes review articles on recent patents in the field of CNS drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on CNS drug discovery is also included in the journal. The journal is essential reading for all researchers involved in CNS drug design and discovery.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more